Parampara Capital

Parampara Capital is a Hyderabad-based early-stage Indian venture firm with a focus on technological advancements and AI applications, operating at seed and Series A with checks in the $1M to $5M range and an explicit AI lens. Healthcare interest centers on digital health and AI/ML in healthcare, with the fund’s geographic positioning in Hyderabad creating natural deal flow from the city’s deep biotech, pharma, and clinical research ecosystem. The right founder for Parampara is an Indian technical operator, often emerging from Hyderabad’s pharma, biotech, or technology talent pool, building defensible AI software for clinical, diagnostic, or pharma-adjacent workflows with B2B distribution. The wrong founder is a consumer wellness brand, a deep biotech team needing scientific syndicate construction at scale, or a US-pedigreed founder using India only as an engineering hub. Intro paths run through Hyderabad’s distinct technology and life-sciences operator network including the T-Hub and IIIT-Hyderabad ecosystems, the broader Indian healthcare AI community connected to AIIMS and Manipal academic centers, and through frequent co-investors including Endiya Partners, Pi Ventures, Speciale Invest, and Inventus Capital. Cold inbound is read by the team but warm intros materially help. In the pitch, lead with the data moat and model performance evidence, since Parampara’s AI thesis means weak claims will be priced down quickly. Show specific provider deployment patterns, real outcome metrics from pilots, and a credible plan to compound proprietary clinical or pharma data over time. Be explicit about CDSCO posture for any device-classified software, NMC implications for clinical decision support, and your data architecture given India’s evolving DPDPA framework. Be specific about how Hyderabad’s pharma corridor including Dr. Reddy’s, Aurobindo, and Bharat Biotech might create commercial relationships for your business if relevant. Caveats include the fund’s relatively concentrated portfolio approach which means partner attention is real but selective, the increased competitiveness of Indian Series A AI rounds in 2024-2025, and the reality that healthcare AI businesses in India face structural data access and standardization challenges that can slow product velocity. For India-native healthcare AI operators with strong technical foundations, Parampara is a credible early partner with regional expertise.